Mustang Bio, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $468,000, a significant reduction from the $1.4 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company incurred a net loss of $1.4 million, down from $14.8 million in the prior year. The decrease in losses is attributed to a substantial reduction in research and development expenses, which fell to $1.2 million from $8.2 million, primarily due to workforce reductions and the termination of certain clinical trials. General and administrative expenses also decreased by 32% to $957,000 compared to $1.4 million in the previous year.
The company’s cash and cash equivalents increased to $19 million as of September 30, 2025, up from $6.8 million at the end of 2024. This increase was bolstered by financing activities, which generated $14.5 million during the nine-month period, primarily from a public equity offering and warrant exercises. Mustang Bio's accumulated deficit now stands at $398.1 million, raising concerns about its ability to continue as a going concern without additional funding.
Strategically, Mustang Bio has made significant changes, including the termination of its lease for the Plantation Street Facility and the sale of related assets to preserve capital. The company is focusing on its CAR T therapy pipeline, which includes partnerships with leading research institutions such as the City of Hope and Fred Hutchinson Cancer Center. In October 2023, the FDA accepted Mustang's IND application for its combination therapy MB-109, which is aimed at treating glioblastoma. However, the company is currently negotiating the terms of a potential termination of its CD20 License with Fred Hutch due to unpaid patent expenses.
Operationally, Mustang Bio has reduced its workforce and is actively pursuing additional funding through equity offerings and collaborations to support its clinical programs. The company has not generated any revenue from its product candidates to date and does not anticipate doing so in the near future. The outlook remains cautious, with substantial doubt about its ability to continue operations without raising additional capital. The company is also subject to various risks, including regulatory challenges and competition from other biopharmaceutical firms, which could impact its future growth and market position.
About MUSTANG BIO, INC.
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company developing innovative cell therapies, primarily CAR T treatments for cancers and autoimmune diseases. Its pipeline includes therapies targeting glioblastoma, hematologic malignancies, and autoimmune conditions, often in partnership with leading research institutions. The company focuses on licensing advanced technologies, supporting clinical trials, and commercializing targeted immunotherapies to address unmet medical needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.